Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14777294 | 0.94 | LMNA (0.50) | TAAR1RAB9ANPC1LMNAHTT | |
| SCHEMBL14776904 | 0.94 | LMNA (0.50) | TAAR1RAB9ANPC1LMNAHTT | |
| SCHEMBL11851172 | 0.89 | CALM1 (0.51) | TAAR1RAB9ANPC1LMNAHTT | |
| SCHEMBL29644736 | 0.88 | TAAR1 (0.67) | TAAR1ALDH1A1CALM1GAACYP2D6 | |
| SCHEMBL834910 | 0.88 | TAAR1 (0.67) | TAAR1ALDH1A1CALM1GAACYP2D6 | |
| SCHEMBL19441517 | 0.86 | LMNA (0.42) | TAAR1RAB9ANPC1LMNAHTT | |
| SCHEMBL19441519 | 0.86 | LMNA (0.42) | TAAR1RAB9ANPC1LMNAHTT | |
| SCHEMBL3108886 | 0.85 | HDAC1 (0.51) | TAAR1RAB9ANPC1LMNAHTT | |
| SCHEMBL20225729 | 0.83 | PDCD1 (0.57) | TAAR1RAB9ALMNAHTTALDH1A1 | |
| SCHEMBL695934 | 0.83 | PDCD1 (0.57) | TAAR1RAB9ALMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| CN-114174263-B | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2022-07-07 | — | — | US | disclosed |
| EP-3966199-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2022-03-16 | — | — | EP | disclosed |
| CN-114174263-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2020229968-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2020-11-19 | — | — | WO | disclosed |
| US-20170174922-A1 | CONDUCTIVE MATERIAL AND SUBSTRATE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-06-22 | — | — | US | disclosed |
| US-9394273-B2 | Therapeutic prostaglandin receptor agonists | ALLERGAN, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150329518-A1 | THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS | ALLERGAN, INC. | 2015-11-19 | — | — | US | disclosed |
| WO-1991010650-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES | PFIZER LIMITED (GB) | 1991-07-25 | — | — | WO | disclosed |
| EP-0364123-B1 | MUSCARINIC RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 1991-06-12 | — | — | EP | disclosed |
| CN-1045580-A | Pyrrolidin derivatives | PFIZER (US) | 1990-09-26 | — | — | CN | disclosed |
| EP-0388054-A1 | Pyrrolidine derivatives | Pfizer Limited (GB) | 1990-09-19 | — | — | EP | disclosed |
| WO-1990004583-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1990-05-03 | — | — | WO | disclosed |
| EP-0365093-A1 | Muscarinic receptor antagonists | PFIZER INC. (US) | 1990-04-25 | — | — | EP | disclosed |
| CN-1041583-A | MUSCARMIC RECEPTOR ANTAGONISTS | PFIZER (US) | 1990-04-25 | — | — | CN | disclosed |
| EP-0364123-A1 | Muscarinic receptor antagonists | Pfizer Limited (GB) | 1990-04-18 | — | — | EP | disclosed |
| CN-1039415-A | New 1, the preparation method of 3-3-disubstituted piperidine derivatives | PFIZER (GB) | 1990-02-07 | — | — | CN | disclosed |
| EP-0350309-A1 | Piperidine derivatives | Pfizer Limited (GB) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | TAAR1 4166/4885RAB9A 582/4885NPC1 69/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | TAAR1 3573/4885RAB9A 498/4885NPC1 14/4885 |
| US-20150329518-A1 | THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS | PTGIR, PTGDR, PTGFR | TAAR1 197/4885RAB9A 2133/4885NPC1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.